Bristol-Myers Squibb Co.
BMY
Market Cap$89.25B
Close$
Earnings Call Q4 2023
February 2, 2024 - AI Summary
Q4 2023 was a strong quarter for Bristol-Myers Squibb (BMS), with 9% growth and nearly $10 billion in revenue, driven by sales momentum in their inline and new product portfolio.
BMS expects to grow their business in 2024, with revenues projected to increase in the low-single digit range. They anticipate continued strong demand for key products like Opdivo and Eliquis.
The company is focused on executing their strategy to navigate LOEs (loss of exclusivity) and maximize the potential of their growth portfolio. They aim to minimize the transition period and accelerate R&D programs to deliver sustainable top-tier growth in the latter part of the decade.
Exclusive for Stockcircle Pro members
Sign up
$57.51
30.6% upside
Current Fair Value
30.6% upsideUndervalued by 30.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $89.25 Billion |
|---|---|
| Enterprise Value | $135.26 Billion |
| Dividend Yield | $2.3015 (5.23%) |
| Earnings per Share | $-2.99 |
| Beta | 0.0 |
| Outstanding Shares | 2,027,100,096 |
| Avg 30 Day Volume | 14,748,817 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -14.52 |
|---|---|
| PEG | 2.32 |
| Price to Sales | 2.0 |
| Price to Book Ratio | 5.5 |
| Enterprise Value to Revenue | 2.97 |
| Enterprise Value to EBIT | 17.95 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.41 |
| Debt to Equity | 3.38 |
Revenue Sources
No data
ESG Score
No data
About Bristol-Myers Squibb Co.
30,250 employees
CEO: Giovanni Caforio Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.